News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL
10 Jul 2026
byAudrey Abella
The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.








